Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvorexant for Brain Reactivity in Cannabis Use Disorder
NCT06584942Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of suvorexant in cannabis use disorder (CUD), sponsored by Massachusetts General Hospital. Primary endpoint: Change in Insula Activation to Cannabis Cues During a Cue Reactivity Task Measured by fMRI at Day 14. Started Mar 2025; status: completed.
02
Drugs
suvorexant
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT06584942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06584942.